Campath (alemtuzumab) / Bayer, Sanofi - LARVOL DELTA

Thyroid Storm Following Alemtuzumab-based Allogeneic Stem Cell Transplantation: A Case Report and Literature Review. (PubMed, Intern Med) - "Despite prompt engraftment, mixed T-cell chimerism and insufficient immune regulation may have contributed to the early onset and severity of the thyroid storm. Careful monitoring of the thyroid function and immune chimerism might facilitate the early detection and management of post-transplant autoimmune complications, including thyroid storm, in patients receiving alemtuzumab-based conditioning."

Journal • Aplastic Anemia • Bone Marrow Transplantation • Endocrine Disorders • Hematological Disorders • Immunology • Transplant Rejection • Transplantation

Autoimmune complications of lymphoproliferative diseases (ICML 2025) - "Moreover, several drugs may be responsible for immune-mediated cytopenias, including several antibiotics (ceftriaxone, piperacillin, rifampin, nafcillin, erythromycin, ticarcillin, trimethoprim, sulfamethoxazole), and various other drugs (procainamide, quinine, phenacetin, diclofenac, cimetidine, hydrochlorothiazide, chlorpropamide) [8]...Ibrutinib, through the inhibition of autoantibodies producing B-cells and restoration of T-cell homeostasis seems safe, while some case reports of autoimmune diseases have been reported for idelalisib (autoimmune hepatitis, colitis) and venetoclax (AIHA) [5, 6]...They included nivolumab, followed by pembrolizumab, ipilimumab, and atezolizumab...In particular, in CLL several therapies have been reported effective in refractory cytopenias: alemtuzumab single agent, the combinations ibrutinib-rituximab, bendamustine-rituximab, and rituximab–cyclophosphamide-dexamethasone [34-37]. Notably, some of the new/experimental treatments for primary..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Waldenstrom Macroglobulinemia • CTLA4 • HP • IL10 • PD-1 • TGFB1

Real-world safety and effectiveness of alemtuzumab as a conditioning regimen for hematopoietic stem cell transplantation. (PubMed, Int J Hematol) - "Engraftment was achieved in 55 of 58 patients (94.8%) at a median of 16 days after HSCT, and predefined success (engraftment without grade ≥ 3 graft-versus-host disease in hematologic malignancies or grade ≥ 2 in other diseases) was met in 51 of 58 patients (87.9%). These results support the manageable safety profile and effectiveness of alemtuzumab as preconditioning for HSCT in Japanese patients."

Journal • Real-world evidence • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Neutropenia • Oncology • Transplantation • CD52

COMPARATIVE EFFICACY OF THERAPEUTIC APPROACHES IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2025) - "This meta-analysis evaluates the efficacy of various therapies for RR-PTCL, including Epigenetic modifiers (HDIs, DNA methyltransferase inhibitors, EZH1/2 inhibitors), Small molecule inhibitors (targeting PI3K/AKT/mTOR, JAK/STAT, ALK, aurora kinase, farnesyl transferase), Combination therapies (various multi-class drug combinations), Pralatrexate-based regimens, monoclonal antibodies (e.g., Pembrolizumab, Alemtuzumab, Zanolimumab, etc.) and Others (Acimtamig, CAR T-cell therapy, etc.). This analysis suggests that combination therapies had the highest response rates, with SMI and pralatrexate-based therapies showing the longest OS. Other cytotoxic chemotherapy-based regimens had the lowest effectiveness, which suggests that combined targeted no-cytotoxic treatment regimens should be further studied in R/R PTCL. Outcomes continue to be poor, and clinical trials with novel treatment strategies should be prioritized"

Retrospective data • Review • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EZH2

Persistent lymphopenia after kidney transplantation: increased mortality and decreased homeostatic mechanisms. (PubMed, Front Immunol) - "Kidney transplant (KTx) recipients commonly develop transient lymphopenia due to treatment with alemtuzumab, rabbit anti-thymocyte globulin (rATG) or other conditions. PD-1 expression was increased with decreasing lymphocyte counts in T and B cells and in most T cell subsets including CD4 TSCM, CD4 and CD8 naïve cells, and CD4 recent thymic emigrants. We conclude that persistent lymphopenia might be partially due to impaired homeostatic mechanisms in T, B and NK cells and might be a simple, useful biomarker for individualizing patient management."

IO biomarker • Journal • Retrospective data • Transplantation • CD4 • CD8 • PD-1

Alemtuzumab-Induced Thyroid Eye Disease: Case Series (ENDO 2025) - "Both patients were treated with lubricant eye drops, selenium, and intravenous methylprednisolone, with one requiring Mycophenolate Mofetil (MMF) and Azathioprine as second-line agents before achieving remission. As the use of Alemtuzumab in managing MS increases, the incidence of Al-TED is likely to rise. Al-TED can develop several years after treatment, necessitating a high index of suspicion for timely diagnosis, particularly in cases of mild disease. The potential for significant morbidity in moderate to severe TED underscores the importance of early recognition and appropriate treatment."

Clinical • CNS Disorders • Endocrine Disorders • Grave’s Disease • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • CD52

Lymphoid Malignancies in Ataxia-Telangiectasia: Experience with Novel Targeted Therapies. (PubMed, Pediatr Blood Cancer) - "This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B-cell lymphoma, alemtuzumab for T-cell prolymphocytic leukemia, and venetoclax for early T-cell precursor acute lymphoblastic leukemia. These cases highlight the potential of targeted agents to improve outcomes while minimizing toxicity. Our findings underscore the need for further research to optimize treatment approaches in this high-risk population, offering novel insights into personalized therapy for patients with AT."

Journal • Acute Lymphocytic Leukemia • Ataxia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Movement Disorders • Non-Hodgkin’s Lymphoma • Oncology • Primary Immunodeficiency • Prolymphocytic Leukemia

Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study. (PubMed, Sci Rep) - "IL2R patients also had a significantly shorter hospital admission durations (14 vs. 30 days, p < 0.001). In conclusion, IL2R induction in SPK recipients was associated with similar short-term graft function and potentially improved outcomes compared to ALEM, warranting cautious interpretation due to sample size."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Transplantation • IL2RA

INFECTIOUS COMPLICATIONS OF AGENTS USED IN T-CELL LYMPHOMAS: A DISPROPORTIONALITY ANALYSIS USING THE FAERS DATABASE (EHA 2025) - "The public dashboard of FAERS was queried for reports of infections due to herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), pneumocystis jiroveci (PJP) and cases of hepatitis B (HepB) reactivation and neutropenia associated with mogamulizumab, brentuximab vedotin, vorinostat, romidepsin, praletexate, methotrexate, peginterferon alpha-2a (PEG-IFN alfa-2a) and alemtuzumab when used for the indication of any T-cell lymphoma. Analysis of the FAERS database revealed variability in the reported infectious complications of commonly used agents for TCLs. Among all agents, alemtuzumab had the highest RORs for all infections while vorinostat had statistically significant RORs only for VZV-related infections and neutropenia. Romidepsin, which is a histone deacetylase inhibitor like vorinostat, had RORs that were unexpectedly higher than vorinostat and were comparable with other agents for CMV, HSV and PJP-related infections and neutropenia."

Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Herpes Simplex • Herpes Zoster • Infectious Disease • Lymphoma • Neutropenia • Oncology • T Cell Non-Hodgkin Lymphoma • Varicella Zoster

THERAPEUTIC OUTCOMES IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL): A COLLABORATIVE MULTI-CENTER STUDY COHORT AND GENOMIC ANALYSIS (EHA 2025) - "Other active second-line treatments included: pentostatin (without alemtuzumab) (n=28; 43% ORR, 14% CR), ruxolitinib-based regimens (n=4; 25% ORR, 0% CR), venetoclax-based regimens (n=13; 39% ORR, 8% CR), bendamustine (n=19; 27% ORR, 11% CR), and nelarabine (n=4; 75% ORR, 50% CR).In subgroup analysis, TCL1A+ patients had worse OS and PFS when compared to TCL1A- patients (23 vs 42 months; p=0.01), and (14 vs 28 months; p=0.01), with HR 1.54 (1.10, 2.16) (p=0.01) for OS and HR 1.58 (1.13-2.20) (p=0.01) for PFS. In this large multi-center study of T-PLL, frontline treatment with a combination of alemtuzumab/pentostatin improved ORR and OS. Among patients who attained a CR, allograft improved OS & PFS. In relapsed T-PLL, retreatment with alemtuzumab had a high ORR, and we report significant activity of multiple novel/alternative agents with the largest reported numbers to date."

Clinical • Genomic analysis • Omic analysis • Hematological Malignancies • Leukemia • Oncology • Prolymphocytic Leukemia • CD4 • TCL1A

CLADRIBINE AND VENETOCLAX FOR TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA (EHA 2025) - "Second-line treatment with alemtuzumab, pentostatin, or bendamustine results in ORR of 30%-46%...Six pts (38%) received concomitant alemtuzumab and 7 (44%) received ruxolitinib... A backbone of Clad and VEN represents an active combination in pts with R/R T-PLL including those post-allogeneic SCT who otherwise have limited options. An ORR of 56% with a CRi rate of 25% in a heavily pre-treated population compares favorably to what has been reported among relapsed pts. Prospective analysis of this backbone and correlation of response with disease characteristics is warranted."

Clinical • Hematological Malignancies • Leukemia • Oncology • Prolymphocytic Leukemia • BCOR • IL2RG • JAK1 • JAK3 • STAT5B

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for Prevention and Treatment of Cancer Related Infections, Version 1.2025. (NCCN)

NCCN guideline • Infectious Disease • Oncology

LIS22: AN EFFECTIVE MULTIMODAL POLYCLONAL ANTIBODY TARGETING T-CELL MALIGNANCIES (ICML 2025) - "LIS22 efficacy in vivo were evaluated in NMRI nude mice and SRG rats using T1301 and Jurkat cancer cell lines...In both CDC and apoptosis cytotoxicity assays, LIS22 displayed a significantly higher potency on T cell blood cancers and no toxicity on healthy blood cells compared to Alemtuzumab (Anti-CD52) and Belinostat (HDAC inhibitor)... LIS22 has emerged as a novel and promising antibody for the treatment of T-cell hematologic malignancies. It is currently under clinical investigation (Phase I/II) for the treatment of peripheral T-cell lymphoma (PTCL)."

Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

APLASTIC ANAEMIA: 10 YEAR OUTCOMES IN A SOUTH AFRICAN TRANSPLANT CENTRE. (EHA 2025) - "Six haploidentical transplants, using a modified Baltimore regimen with post-transplant Cyclophosphamide, and one matched unrelated donor transplant, using a Busulfan, Melphalan, Fludarabine protocol with Alemtuzumab in the bag were performed. This retrospective study in adult patients with AA demonstrates the superior outcomes of allogeneic stem cell transplantation compared to immunosuppressive and supportive therapy. The transplant group's 1-year survival outcome align with international findings. Although patients under 14 years were excluded, the median treatment age at our centre is significantly lower than reported globally."

Anemia • Aplastic Anemia • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Solid Tumor • Thymoma • Thymus Cancer • Transplantation

MAAT033 TO ENSURE OPTIMAL GUT MICROBIOTA TO IMPROVE SURVIVAL IN PATIENTS? RECEIVING ALLOGENEIC HCT: PHOEBUS TRIAL (EHA 2025) - "Exclusion criteria comprise non-myeloablative and conventional myeloablative conditioning regimen in vitro T-cell depletion alloHCT with cord blood cells use of alemtuzumab vedolizumab or abatacept for GvHD prophylaxis and history of chronic digestive disease.Study recruitment is currently ongoing in France Germany Spain Belgium The Netherlands and the UK. The PHOEBUS trial explores for the first time the potential of a full microbiota ecosystem therapy to enhance survival in alloHCT recipients. Recruitment is ongoing and preliminary safety assessments are favorable."

Clinical • Gut Microbiota • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology

A COMPUTATIONAL ANALYSIS OF IMMUNE RECONSTITUTION DYNAMICS IN ADULTS WITH SICKLE CELL DISEASE UNDERGOING HLA-IDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (EHA 2025) - "SCD is characterized by altered B and T cell homeostasis, which is only partly restored after nonmyeloablative HSCT. Increased naive/transitional and reduced memory B cells likely result from irreversible vaso-occlusive hyposplenia. Increased expression of PD-1 after HSCT is probably due to T cell depleting conditioning with alemtuzumab."

Clinical • IO biomarker • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Hematological Disorders • Herpes Simplex • Herpes Zoster • Infectious Disease • Pneumococcal Infections • Sickle Cell Disease • Transplantation • Varicella Zoster • CD21 • CD27 • CD4 • CD8 • FOXP3 • PD-1

THREE-MONTH WHOLE BLOOD CHIMERISM INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN ALLOGENEIC STEM CELL TRANSPLANTS FOR HEMATOLOGICAL CANCERS: AN ANALYSIS ON BEHALF OF TWO UK CENTRES (EHA 2025) - "Conditioning regimens incorporated alemtuzumab (n=11 ) antithymocyte globulin (ATG) (n= 1) and post-transplant cyclophosphamide (PTCy) (n= 7). In this two-centre analysis of aSCT for lymphoid and myeloid malignancies full 3-mo BC independently predicted better OS and PFS while full 3-mo TC significantly reduced the CIR at the expense of increased aGVHD and the consequent PFS benefit was lost with longer follow-up. Our findings require further validation as they may inform prospective studies on immunosuppressant tapering or DLI prophylaxis early post-aSCT in high-risk hematological malignancies."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Indolent Lymphoma • Leukemia • Lymphoma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (clinicaltrials.gov) - P1/2 | N=52 | Recruiting | Sponsor: Cellectis S.A. | N=40 ➔ 52 | Trial completion date: Jan 2026 ➔ Jun 2026 | Trial primary completion date: Jan 2026 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

Conditioning regimens for second allogeneic hematopoietic stem cell transplantation for patients with primary graft failure. (PubMed, Transplant Cell Ther) - "A one-day alemtuzumab-based conditioning regimen for salvage HSCT appears to be well tolerated and may be associated with improved engraftment, NRM, and OS when compared to the fludarabine-busulfan-2Gy total body irradiation regimen."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Similar Islet Graft Function with Fewer and Less Severe Side-Effects In Basiliximab Compared to Alemtuzumab Induction Immunosuppression for Islet Transplantation (IPITA 2025) - "Basiliximab results in similar islet graft function as alemtuzumab, but with fewer and less severe side-effects at 3 months post-transplantation."

Adverse events • Infectious Disease • Novel Coronavirus Disease • Transplantation

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Columbia University

New P1 trial • Bone Marrow Transplantation • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Transplantation

Outcome of Simultaneous Pancreas-Kidney Transplant from a Tertiary care center in India (ERA 2025) - "Induction was with Basiliximab in 1 patient, Alemtuzumab in 6 patients and ATG in 6 patients. Maintenance immunosuppression was tacrolimus and mycophenolate in 9 patients; and, tacrolimus, mycophenolate and everolimus in 2 patients... The graft survival and outcomes in our institution is comparable to that of international standards. Surgical complications were noted to be higher compared to renal transplantation. SPK remains to be treatment of choice in T1DM patients with ESRD."

Acute Myelogenous Leukemia • Candidiasis • Cardiovascular • Chronic Kidney Disease • Dental Disorders • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Metabolic Disorders • Nephrology • Obesity • Oncology • Respiratory Diseases • Thrombosis • Transplant Rejection • Transplantation • Tuberculosis • Type 1 Diabetes Mellitus • Varicella Zoster

Caught in a Double Bind: Fungal Infection and Drug-Induced Hepatotoxicity in a Renal Transplant Recipient (UKKW 2025) - "Induction immunosuppression therapy included alemtuzumab and maintenance with tacrolimus monotherapy...Empiric antibiotic (piperacillin-tazobactam) and antifungal (anidulafungin) therapy was initiated...He underwent interventional radiology stenting of the pseudoaneurysm under anti-fungal cover (initially anidulafungin then liposomal amphotericin B)...Liposomal amphotericin B was switched to posaconazole monotherapy but liver function tests (LFTs) worsened (ALP 1233 U/L, bilirubin 247 μmol/L)...Isavuconazole proved to be a well-tolerated alternative, highlighting its utility in similar scenarios. The emergence of pharmacogenomic testing, such as for voriconazole metabolism, may allow for tailored treatment in the future."

Clinical • Cardiovascular • Hepatology • Infectious Disease • Liver Failure • Transplantation

Kidney Transplant Immune Responses study (KTIR): a prospective sample collection from kidney transplant recipients in Cardiff (UKKW 2025) - "Indeed, commonly used induction agents include anti-thymocyte globulin and Alemtuzumab (anti-CD52) which rapidly deplete lymphocytes...Conclusions KTIR provides a platform for the laboratory study of early complications of transplantation. Future directions could include analysis of immune reconstitution after transplantation, antibody and T-cell mediated rejection, and other opportunistic infections."

Clinical • Infectious Disease • Oncology • Transplantation

Lymphocyte depletion post alemtuzumab administration in imlifidase enabled transplants; a UK wide case series (UKKW 2025) - No abstract available

Clinical • Transplantation